Capital Markets Investors

Capstone's Capital Markets Advantage

Proposed regulation and a burgeoning activist philosophy on the part of regulators is transforming industry. Our team complements its expertise in policy and politics with substantial investment buy-side and sell-side experience. We rigorously identify and quantify regulatory and political risks and opportunities in a wide swath of companies and specific transactions, providing differentiated insight in the process.

We dig deeper

Our process always involves a deep-dive analysis of state, federal, and international, and global policy. Our analysts mine news outlets, legislation, events, and other public resources to come up with unique investment ideas with a policy angle. We leverage our extensive outreach to relevant industry associations, advocacy groups, regulators, policymakers, and think tanks to gain a solid understanding of the relevant political landscape and the issues at hand. Our analysts focus on the minutiae of public policy by reading and reviewing public documents, including proposed rules and comment letters, proposed and enacted legislation, as well as policy meetings and hearings.

Services We Engage

We engage

Our analysts regularly consult with our clients to help them understand important policy issues. An engagement with Capstone includes the ability to request ad-hoc policy research on existing and potential investments. At the direction of clients, our team can quickly identify key regulatory issues impacting investments. We treat client requests with complete confidentiality. Our focus on a fee-based model, rather than one requiring us to drive trading volume among our clients, allows us to maintain a more compact customer base permitting a more robust dialogue with our clients than our peers.

 Contact Us

Our Latest Insights

Untangling the Outlook for NIH Funding and Its Impact on Pharma

Untangling the Outlook for NIH Funding and Its Impact on Pharma

Capstone believes funding for the National Institutes of Health (NIH) will remain stable for the next 3-5 years, and investors should look past headline appropriations to specific therapeutic area (TA) to assess regulatory risk. Congress continues to insulate funding...

The IRS Ruling Targeting Tax-Aware ETF Strategies

The IRS Ruling Targeting Tax-Aware ETF Strategies

We believe the Internal Revenue Service’s (IRS) September 28th ruling taxing certain Section 351 transactions signals further restrictions on other aggressive tax-aware strategies over the next two years, which is a negative for exchange-traded fund (ETF) sponsors and...